<?xml version="1.0" encoding="UTF-8"?>
<p>All children born to women with confirmed or probable ZIKV infection in pregnancy were followed-up to determine their clinical outcomes. According to standard of care, all of the participants were offered follow-up for their children at 1, 4, 9, 12, 18, and 24 months of age. This usually included neurological development assessment, ophthalmologic and hearing test, serological testing, cerebral US, MRI, and AABR test. Demographic, anthropometric, clinical, and laboratory data were collected for all the children born to ZIKV infected mothers. We defined an infant as a CZS case when she/he had any of the severe neurologic birth defects included in the currently proposed definition of CZS [
 <xref rid="B4-pathogens-09-00352" ref-type="bibr">4</xref>,
 <xref rid="B17-pathogens-09-00352" ref-type="bibr">17</xref>].
</p>
